Dr. Logan Discusses Treatment Options in CLL

Aaron Logan, MD, PhD
Published: Tuesday, Dec 19, 2017



Aaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses treatment options for patients with chronic lymphocytic leukemia (CLL).

CLL remains the most common leukemia in adults, says Logan. This has led to a lot of innovative therapy, such as monoclonal agents and chemoimmunothearpy.

Additionally, patients with genetic abnormalities such as 17p deletion and p53 now have targeted agents like venetoclax (Venclexta), as these mutations do not respond well to chemoimmunotherapy.
 


Aaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses treatment options for patients with chronic lymphocytic leukemia (CLL).

CLL remains the most common leukemia in adults, says Logan. This has led to a lot of innovative therapy, such as monoclonal agents and chemoimmunothearpy.

Additionally, patients with genetic abnormalities such as 17p deletion and p53 now have targeted agents like venetoclax (Venclexta), as these mutations do not respond well to chemoimmunotherapy.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x